Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122548 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
A Phase 2 study, sponsored by Aduro Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03122548: Clinical Trial Phase 2 study, sponsored by Aduro Biotech.
NCT03122548 is a Phase 2 study that was terminated before completion, run by Aduro Biotech. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122548, a Phase 2 study, was terminated before completion, sponsored by Aduro Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CRS-207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122548
The ClinicalTrials.gov registry entry for NCT03122548 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03122548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122548 about?
NCT03122548 is a clinical study titled "Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers". The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.
What is the current status of trial NCT03122548?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-08-14. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03122548?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CRS-207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03122548?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.